关键词：帕金森氏病；进行性；神经变性疾病；多巴胺能神经元；左旋多巴
摘 要：Parkinson’s disease is a progressive neurodegenerative disorder characterized by damage to the dopaminergic neurons located in various parts of the brain, including the substantia nigra. This lowers the concentration of dopamine in the striatum by 80 percent. This decrease in dopamine levels leads to symptoms associated with Parkinson’s disease such as tremors, bradykinesia, and muscular rigidity. It is usually diagnosed at the age of 60; however, earlier incidence has been reported. Based on the severity, it can be categorized into the early-stage, mid-stage, and late-stage disease. Currently, approved therapies provide only symptomatic relief for the disease. Levodopa is the standard drug for the treatment of Parkinson’s disease;however, it is associated with the incidence of dyskinesias. Alternative surgical procedures such as bilateral globus pallidus interna stimulation and bilateral subthalamic nucleus stimulation can be used in Parkinson’s disease patients under certain circumstances.
目 录：

01. Executive Summary

02. List of Abbreviations

03. Scope of the Report

03.1 Market Overview

03.2 Product Offerings

04. Market Research Methodology

04.1 Market Research Process

04.2 Research Methodology

05. Introduction

06. Market Landscape

06.1 Market Overview

06.2 Market Size and Forecast

06.3 Five Forces Analysis

07. Market Segmentation by MOA

07.1.1 Anticholinergics

07.1.2 Beta-adrenergic Antagonists

07.1.3 COMT Inhibitors

07.1.4 Dopamine Agonists

07.1.5 Dopamine Replenishers

07.1.6 MAOB Inhibitors

07.1.7 Others

08. Geographical Segmentation

09. Buying Criteria

10. Market Growth Drivers

11. Drivers and their Impact

12. Market Challenges

13. Impact of Drivers and Challenges

14. Market Trends

15. Trends and their Impact

16. Vendor Landscape

16.1 Competitive Scenario

16.1.1 Key News

16.1.2 Mergers and Acquisitions

16.2 Market Share Analysis 2013

16.2.1 Novartis

16.2.2 Boehringer Ingelheim

16.2.3 Teva Pharmaceutical Industries

16.2.4 GlaxoSmithKline

16.3 Other Prominent Vendors

17. Late-stage Pipeline Candidates

17.1 Key Information for Late-stage Pipeline

Candidates

17.1.1 ABT-SLV187

17.1.2 BIA 9-1067

17.1.3 IPX066

17.1.4 KW-6002

17.1.5 NW 1015

17.1.6 OS-320

17.1.7 P2B 001

17.2 Key Late-stage Discontinued Drug Candidates

18. Key Vendor Analysis

18.1 Boehringer Ingelheim

18.1.1 Key Facts

18.1.2 Business Overview

18.1.3 Business Segmentation

18.1.4 Business Strategy

18.1.5 Revenue by Business Segmentation

18.1.6 Sales by Geography

18.1.7 Key Information

18.1.8 SWOT Analysis

18.1.9 Strengths

18.1.10 Weaknesses

18.1.11 Opportunities

18.1.12 Threats

18.2 GlaxoSmithKline

18.2.1 Key Facts

18.2.2 Business Overview

18.2.3 Business Segmentation

18.2.4 Business Segmentation by Revenue 2012 and 2013

18.2.5 Sales by Geography

18.2.6 Pipeline Products

18.2.7 Business Strategy

18.2.8 Key Information

18.2.9 SWOT Analysis

18.2.10 Strengths

18.2.11 Weaknesses

18.2.12 Opportunities

18.2.13 Threats

18.3 Novartis

18.3.1 Key Facts

18.3.2 Business Overview

18.3.3 Business Segmentation by Revenue 2013

18.3.4 Business Segmentation by Revenue 2012 and 2013

18.3.5 Sales by Geography

18.3.6 Business Strategy

18.3.7 Key Developments

18.3.8 SWOT Analysis

18.3.9 Strengths

18.3.10 Weaknesses

18.3.11 Opportunities

18.3.12 Threats

18.4 Teva Pharmaceutical Industries

18.4.1 Key Facts

18.4.2 Business Overview

18.4.3 Business Segmentation by Revenue 2013

18.4.4 Business Segmentation by Revenue 2012 and 2013

18.4.5 Sales by Geography

18.4.6 Business Strategy

18.4.7 Key Developments

18.4.8 SWOT Analysis

18.4.9 Strengths

18.4.10 Weaknesses

18.4.11 Opportunities

18.4.12 Threats

19. Other Reports in this Series